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Summary
Background: The oral bis (acetate) ammine dichloro cyclo-
hexylamine platinum (IV) analogue (BMS-182751) was brought
into clinical development because it was shown to be cytotoxic
against some human tumour cell lines and to have an antitu-
mor activity in murine tumours at least comparable to that of
parenteral cisplatin and carboplatin. In early clinical studies
in which the optimal schedule of treatment was daily for five
consecutive days, dose-dependent nausea and vomiting oc-
curred in about two-thirds of patients.
Patients and methods: To evaluate if the use of lower daily
doses for longer periods of time could result in a better toler-
ability, JM216 was given once daily for 14 consecutive days
every four to five weeks to adult patients with solid tumors.
Oral antiemetics were given prophylactically only at the highest
doses. The pharmacokinetics of total and ultrafiltrable platinum
were studied on days 1 and 14 of the first cycle by Inductively
Coupled-Mass-Spectrometry (ICP-MS).
Results: Forty-six patients were treated at doses ranging
from 10 mg/m2/d to 50 mg/nr/d and 39 were evaluable for
hematologic toxicity over 74 cycles. MTDs were reached at 45
mg/m2/d and 50 mg/m2/d x 14 repeated every five weeks in
patients with extensive, or limited/no prior treatment, re-
spectively. The dose-limiting toxicity was neutropenia which
was delayed and variable among patients. Other non-hemato-
logical toxicities were severe vomiting (22% of cycles), diarrhea
(28% of cycles) and drug-associated fever (32% of patients),
controlled with paracetamol. Subjective improvement with
disappearance of tumour-related pain was observed in one
patient with chemotherapy-resistant metastatic prostate can-
cer and in one previously untreated patient with malignant
mesothelioma. Cmax and AUC values of both total and ultra-
filtrable platinum on days 1 and 14 were highly variable among
patients. Only Cmax on day 1 was linearly related to the dose.
Total and ultrafiltrable platinum were still detectable two weeks
after the last dose. No relationship could be established be-
tween AUC values and toxicities.
Conclusions: Daily doses of JM216 of 40 mg/m2 and 45
mg/m2 for 14 consecutive days every five weeks with oral
antiemetic prophylaxis are selected for phase II evaluation of
single agent in patients with extensive or limited/no prior treat-
ment, respectively. The administration of JM216 on a day x 14
schedule produced nausea and vomiting comparable to that
observed with the day x 5 regimen but of longer duration. The
variability of pharmacokinetics and pharmacodynamics, even
though limited at the doses proposed for phase II evaluation of
JM216 as single agent, recommend a careful monitoring of the
patients.
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Introduction
A variety of oral analogues of known antitumour agents
has been developed in the past few years for economic,
pharmacological and practical reasons. To merit further
clinical development the oral analogue should have a
preclinical antitumour activity and toxicity comparable
to those of the parent compound, no or only limited
gastrointestinal (GI) toxicity, acceptable bioavailability,
safe and reproducible pharmacokinetic profile.
A series of ammine/amine platinum (IV) dicarboxy-
lates of higher lipophilicity and stability than cisplatin
and carboplatin has been developed in an effort to im-
prove absorption and to decrease the metabolic activa-
tion through processes in the GI tract. The oral bis
(acetate) ammine dichloro cyclohexylamine platinum
(IV) analogue (BMS-182751, JM216; Figure 1) was
introduced into clinical development because it was
shown in vitro to be toxic to some human tumour cell
lines [1] and to have an antitumour activity in rodent
tumours at least comparable to that of parenterally
administered cisplatin and carboplatin.
In one murine and one human tumor model, a sched-
ule dependency of the antitumor activity was shown, the
daily x 5 administration producing tumor growth delay
and tumor regression superior to those observed after
single intermittent or chronic indefinitely dosing [2].
Myelosuppression, mainly neutropenia and thrombo-
cytopenia, was dose-limiting in mice, while nephrotox-
icity was comparable to that of i.v. carboplatin in mice
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Figure 1. Chemical structure of JM216.
and rats [3]; there was no neurotoxicity [4]. The emetic
potential was higher in dogs, but comparable to that of
carboplatin in ferrets, and could be partially controlled
by the administration of ondansetron. The bioavailabil-
ity of JM216 in animals could not be assessed due to its
high insolubility and production of a series of metabo-
lites, some of them still cytotoxic; it was shown, how-
ever, that cytotoxic concentrations of platinum could be
achieved in plasma ultrafiltrate in mice.
In humans JM216 was first studied on a single inter-
mittent schedule, subsequently abandoned because of
non-linear pharmacokinetics with saturable absorption
and dose-limiting nausea and vomiting [5]. A daily ad-
ministration for 5 consecutive days to improve absorp-
tion and tolerability was then evaluated, and its effec-
tiveness was later confirmed [6]. The maximum tolerable
dose (MTD) was fixed at 140 mg/m2/d, and daily doses
of 100 mg/m2 and 120 mg/m2 for, respectively, previ-
ously treated and untreated patients were recommended
for phase II studies. Myelosuppression was dose-limiting
and non-cumulative, while two-thirds of the patients
presented nausea and vomiting despite antiemetic pro-
phylaxis, and diarrhea, in most instances mild to moder-
ate. Pharmacokinetic studies showed a linear pharmaco-
kinetics with a high interpatient variability and a signifi-
cant correlation between plasma ultrafiltrate AUC and
degree of thrombocytopenia.
Evaluation of lower daily doses administered over
longer time periods was begun in an effort to further
decrease GI toxicity and to develop an oral platinum
regimen suitable for combination with cytotoxic agents
or radiation. A two-week period of treatment was chosen
because it could provide an adequate exposure time with
an acceptable degree of GI toxicity.
Patients and methods
Patients
Adult patients, aged 18 to 75 years, with histologically/cytologically-
confirmed diagnoses of solid tumours not amenable to conventional
local or systemic treatments were eligible for this trial. Patients must
have recovered from the toxic effects of prior therapy, with a treatment-
free period of at least four weeks for those who had received chemo-
therapy (six for those given nitrosoureas, carboplatin. mitomycin) and
eight for those who had undergone large field irradiation. Eligibility
criteria also included an ECOG performance status (PS) of < 2, life
expectancy of > 3 months, no previously severe or unresolved toxic
effects of cisplatin or carboplatin, adequate bone marrow (neutrophil
count (ANC) > 2 0 x 103/ul. platelet count > 100 x 103/ul). liver
(bilirubin <25 umol, ALT and alkaline phosphatase ^1.5 x normal,
unless secondary to malignancy, for which a value ^ 2.5 x normal was
acceptable) and renal function (24-hour creatinine clearance between
73 and 120 ml/min). feasibility and willingness to participate in phar-
macokinetic studies, written informed consent. Serious concomitant
medical disease, gastrointestinal disorders likely to hamper drug ab-
sorption, and significant ECG abnormalities were criteria for exclusion.
Study design
A starting dose of 10 mg/m2, corresponding to the daily dose to be
given for two weeks if the MTD was 140 mg/m2 as found in the day x 5
study, was selected. Treatment was first scheduled every four weeks or
when a ANC of 5 2.0 x 103/ul had been reached, whichever occurred
first. Because of the subsequent observation of delayed neutropenia
and thrombocytopenia, the protocol was amended and patients were
treated again after at least four weeks if the ANC and platelet counts
had begun to increase and were (of) 3=2.0 x 103/uI and > 100 x IO3/ul,
respectively. From the 35 mg/m2 dose onward treatment was scheduled
every five weeks. At least three patients, and six in case of grade 5= 3
haematologic or GI toxicity or of other non-haematologic toxicity of
grade > 2, had to be evaluable for toxicity at each dose level. At least
two weeks had to elapse between completion of treatment of the first
patient and the entry of other patients at the same dose level; at least
three patients per dose level had to be evaluable after one cycle prior to
opening of the next higher dose level. Intrapatient dose escalation was
not allowed. The dose was increased by 25%—100% increments accord-
ing to the degree and variability of the haematologic toxicity observed.
The dose was reduced at subsequent cycles in instances of myelo-
suppression of grade 5:3, non-haematologic toxicity (except for nausea
and vomiting) of grade >2 . Treatment was discontinued in instances
of non-haematologic toxicities of grade ^ 3 .
Chemistry (including electrolytes, calcium, creatinine, urea, total
protein, albumin, bilirubin, transaminases, alkaline phosphatase) and
urinalyses were repeated weekly, and CBC counts with differential
more often in case of toxicity. Twenty-four-hour creatinine clearance
was repeated before each cycle. Baseline ECG, audiometry and tumour
measurements were requested.
Toxicity was evaluated according to the National Cancer Institute
(NCI) Common Toxicity Criteria.1 When no CTC criteria were avail-
able, a score of mild, moderate or severe was assigned. Patients were
asked to keep a log of symptoms during the chemotherapy period,
especially with respect to GI symptoms.
Patients were evaluable for haematological toxicity if they had
received at least 12 days of treatment and if at least weekly CBC counts
with differential were available for a minimum of four weeks; patients
were evaluable for non-haematological toxicity after at least one day of
treatment; retreatment cycles at lower doses were not included in the
toxicity analyses which were performed per dose level.
The MTD was defined as the dose at which two or more of six
patients developed either haematological or GI toxicity of grade ^ 3. or
non-haematological toxicity (excluding GI) of grade > 2 . Additional
patients were treated at the dose recommended for phase II studies,
which was one step below the MTD, to define risk factors and degree
of toxicity variability.
In patients with measurable or evaluable disease tumour response
was assessed after two cycles and classified according to WHO criteria
[7]. Patients with stable disease or tumour response continued treatment
with JM216 until tumour progression or unacceptable toxicity. which-
ever occurred first, while patients with progressive disease went off study.
Drug administration
JM216 was supplied by Bristol-Myers Squibb Company (Wallingford,
CT) as 10 and 50 mg hard gelatin capsules with excipients (micro-
crystalline cellulose, sodium starch glycolate. lactose, and magnesium
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Table I. Patient characteristics
Characteristics
Total number of patients
Sex
Female
Male
Age (in years)
Median
Range
Prior therapy
Chemotherapy alone
Chemo + radiotherapy
Radiotherapy
None
Tumour types
Colorectal
Non-small-cell lung cancer
Ovary
Other
Number of patients
46
14
32
57
29-74
23
12
3
14
11
4
17
Table 2. Patients and cycles evaluable for hematologic toxicity.
Dose (mg/m2) Patients Evaluable cycles
Daily Total En- Evalu- ^ 2 Initial Subsequent
tered able evaluable
cvcles
10
20
30
35
40
45
50
Total
140
280
420
490
560
630
700
5
3
7
10
7
8
6
46
5
3
5
9
6
6
5
39
3
3
2
4
4
4
3
23
5
3
5
8"
6
6
5
38
3
5
5
4
4
5
10
36
a
 First cycle only not evaluable because of treatment discontinuation
due to severe nausea and vomiting.
stearate). Capsules were packaged in light-resistant bottles and stored
at +2 to —30 °C. The number of capsules to be taken daily was based on
the dose level, the patient's body surface area (BSA), the total dose to
be given over 14 days, and the attempt to maintain as constant as
possible the number of capsules to be taken each day, with the rule of
administering the highest dose on the first day, and identical doses on
the days when pharmacokinetics was assessed. Patients were given a
chart with the number of capsules to be taken each day. and asked to
refrain from eating solid food from the previous midnight up to four
hours after dosing on the days when pharmacokinetic studies were to
be performed. On the other days, patients were asked to take the
JM216 at the same time each day and to eat no solid food for at least
one hour afterward. Administration of antiemetic prophylaxis with
5-HT3 antagonists was started at 35 mg/m2 because of the occurrence
of moderate nausea and vomiting at the previous dose; antiemetics
were given I.V. on the days when pharmacokinetics was assessed, while
the oral route was recommended for the other days of treatment. Oral
loperamide was administered in case of diarrhea, premedication with
oral paracetamol (500 mg t.i.d.) was given to patients suffering from
drug-associated fever and chills.
Pharmacokinetics
formed by Inductively Coupled-Mass-Spectrometry (ICP-MS)' Elan
5000 Perkin Elmer Sciex equipped with Cool flow CFT-75 Neslab,
autosampler AS90. Instrumental specifications and analytical condi-
tions have been reported elsewhere [8].
Biological samples were diluted to varying degrees (I : 10 to 1: 100
v/v) with ultrapure water (Milli-Ro, Mill/Q, Millipore) depending on
the matrix, before analysis. Ir 193, an isotope with chemical-physical
properties similar to those of Pt, was used as internal standard to
eliminate a matrix effect.
A calibration curve was prepared using the standard addition
method by adding Pt standard solutions to plasma for the determina-
tion of total Pt and to ultrapure water for the analysis of ultrafiltrate
and urine. Linear responses were observed for four orders of magni-
tude; the detection limit of the method was 0.001 ng/ml.
Pharmacokinetic analyses
Pt and UPt plasma concentrations determined in each subject were
fitted on a general non-linear fitting program [9] according to one-,
two- or three-compartment open models depending on the data points
available. The experimental area under the curve of concentration vs.
time AUC from time 0 to 24 hours was calculated according to the
trapezoidal method.
Sampling procedure
Pharmacokinetics studies of JM2I6 were performed in all patients on
days 1 and 14 of the first cycle. Blood samples (5 ml) were collected in
tubes containing EDTA before and then at 0.5, one, two, three, four,
six, eight, 12 and 24 hours after treatment. In selected cases, additional
samples were collected up to two weeks after the end of the cycle.
Urine fractions (0-8 hours and 8-24 hours) were collected on days I
and 14, their volume measured, and an aliquot of 5 ml kept for analysis.
To prepare plasma, blood was centrifuged at 2000g for 15 min at 4 "C
within 30 min after sampling. Plasma was separated and divided into
two portions, one for determination of total platinum (Pt) and one for
preparation of the plasma ultrafiltrate using AM ICON Centrifree
filters (30.000 MW cut ofT). The filters were centrifuged at 2000 g for
20 min at 4 C and the ultrafiltrate used for determination of the free
fraction of platinum (UPt).
Platinum assay
Plasma, ultrafiltrate and urine samples were thawed in a warm bath
immediately before analysis. Pt and UPt determinations were per-
Results
Forty-six patients with an ECOG Performance Status of
0-1 entered the study; their characteristics are listed in
Table 1. The most frequently represented tumour types
were colorectal in 14 patients, and non-small-cell lung
cancer in 11 patients, seven of whom had received no
prior chemotherapy and were treated at the two highest
dose levels. Thirty-five patients had already received
chemotherapy, 12 of them with cisplatin and/or carbo-
platin. Six of eight patients were given JM216 at the
MTD as first antitumour treatment.
Hematologic toxicity
A total of 39 patients and 74 cycles were evaluable for
hematologic toxicity (Table 2). Seven patients (15%)
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Table 3 Severe neutropenia, median neutrophil nadir (x 103/ul) and median time to nadir (days) per dose level.
Dose (mg/m2) Number of evaluable Number of patients with CTC toxicity ANC nadir at cycle
patients/cycles
10a
20a
30a
35a
40a
45b
50c
5/8
3/8
5/10
9/12
6/10
6/11
5/15
1
2
1
2
1
ANC nadir at cycle
First !
3.2 (2.0-4 77)
4.3(4.0-5.1)
1.35(0.6-1.6)
2 2 (0.6-3.4)
2.2(1.5-3 4)
2.4 (0.9-4.9)
2.4 (0.9-4.6) I
Subsequent
.9(1.4-5.8)
.6(1.2-2.1)
.1(1.0-1.8)
0 (0.5-2.2)
.7(0.1-4.5)
.1 (0.4-1.8)
1.4 (0.3-2.8)
Time to nadir
first cycle
23(14-29)
15(14-29)
35(22-43)
29(1-35)
27(16-41)
28(21-40)
32 (2-44)
Prior chemotherapy: a > 2 regimens; b ^ 2 regimens; c none.
Table 4. Severe thrombocytopenia, median platelet nadir (x 103/ul) and median time to nadir (days) per dose level
Dose (mg/m2) Number of evaluable Number of patients with CTC toxicity Platelet nadir at cycle Time to nadir
10a
20a
30a
35a
40a
45b
50c
patienis/cycies
5/8
3/8
5/10
9/12
6/10
6/11
5/15
Prior chemotherapy: a < 2 regimens; b
3
3
1
1
^ 2 regimens; c none.
4
1
2
1
First
208(170-365)
195(167-196)
48(37-115)
134(12-200)
85(15-104)
106(64-149)
150(122-197)
Subsequent
146(123-328)
143(139-197)
72(61-107)
99(50-159)
105(9-173)
61(41-88)
133(18-256)
nrsi cycie
14(13-23)
14(14-28)
31(29-33)
30(26-36)
30(19-36)
29(28-34)
28(10-31)
received less than 13 days of therapy at the first cycle and
were not included in the analysis of hematologic toxicity
at this cycle. None of these patients showed hematologic
toxicity. Treatment was interrupted in two patients
treated at 30 mg/m2 because, respectively, of dizziness
and tumor-related early death, in one patient at 35 mg/
m2 due to grade 3 vomiting, in one at 40 mg/m2 due to
uncontrolled drug-related fever with chills, in two at 45
mg/m2 due, respectively, to grade 3 vomiting and tumor-
related early death, and in one at 50 mg/m2 because
of drug-related fever with chills. In all patients but one
treatment with JM216 was then definitively discontinued.
The dose-limiting toxicity was neutropenia, with grade
3 neutropenia first observed at 30 mg/m2 in pretreated
patients; grade 3-4 neutropenia occurred in three of six
patients with limited prior chemotherapy (<2 regimens)
at 45 mg/m2 and in two of five with no prior chemo-
therapy at 50 mg/m2, thereby defining the MTD in these
groups of patients (Table 3). The overall median time to
nadir was between days 27 and 35, with recovery in 7 to
10 days. Severe neutropenia was always associated with
moderate to severe thrombocytopenia. Overall, neutro-
penia showed a wide interpatient variability only partly
related to the extent of prior treatment; at 50 mg/m2,
where JM216 was given as first treatment in all patients,
neutrophil nadir counts ranged from 0.3 x 103/ul to
4.6 x 103/ul.
Thrombocytopenia showed a comparable profile,
with a median time to nadir between days 28 and 31,
and recovery in the subsequent seven to 10 days (Table 4).
The dose had to be reduced at the second cycle in one
heavily pretreated patient receiving 30 mg/m2/d because
of grade 3 thrombocytopenia. Severe thrombocytopenia
was sporadic at the MTDs because of the more favor-
able selection of patients. In another patient, heavily
pretreated at 45 mg/m2, and in one previously untreated
at 50 mg/m2, the dose had to be decreased by one dose
level after three and two cycles, because, respectively, of
grade 3 and grade 4 thrombocytopenia.
In one of three patients who received repeated cycles
at 20 mg/m2/d and in all five patients treated at 30
mg/m2/d treatment could not be resumed every four
weeks because of delayed hematological recovery. From
35 mg/m2/d onward, JM216 was given every five weeks
with only two cycles at 40 mg/m2/d requiring a further
delay because of persisting thrombocytopenia.
Anemia was first observed at 35 mg/m2/d; 50% of the
patients treated at between 35 mg/nr/d and 45 mg/m2/d
suffered from grade 1-2 anemia with no significant
difference among dose levels.
Non-hematologic toxicity
Nausea and vomiting were the most common non-hem-
atologic side effects, and required antiemetic prophy-
laxis with 5-HT3 antagonists from the dose of 35
mg/m2/d onward (Table 5). Nevertheless, three patients
discontinued the treatment during the first (two pa-
tients) or second cycles (one patient) because of uncon-
trolled nausea and vomiting and 22% of cycles with
doses at ^ 35 mg/m2 were associated with grades 2 or 3
vomiting.
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Table 5. Non-hematologic toxicity per dose level.
Dose
(mg/m2)
10
20
30
35
40
45
50
Number of
evaluable
patients/
cycles
5/8
3/8
7/12
10/15
7/11
8/14
6/16
Number of cycles with toxicity grade
Nausea
1 2 3 4
2
3 1
6 2
3 3
2 3
2 2 lc
7 2
Vomiting
1 2 3 4
1
1 2 1
3 2 3"
1 2 1
5 lc
4
Diarrhea
1 2 3 4
2
5 1
3 3 b 2
1
1
5 1
Drug-
fever
1 2 3
1
1 2
2
lc
1 5
4 r
Antiemetic prophylaxis from 35 mg/m2.
Toxicity requiring treatment discontinuation in aone patient; btwo
patients; cone patient.
Diarrhea was reported in 28% of cycles; it occurred
after at least one week of treatment in most of the
patients and was controlled by oral loperamide. One
patient treated at 35 mg/m2 requested to discontinue
the treatment because of reappearance and worsening of
diarrhea up to grade 2 within 48 hours from the start of
the second cycle.
Drug fever, defined as an intermittent daily increase
of temperature up to ^ 38 °C without concomitant neu-
tropenia or signs of infection, and occurring within four
to six hours after JM216 dosing, was observed in a total
of 15 patients (32%), nine of them treated at doses equal
to or greater than 40 mg/nr/d. In 12 patients drug fever
was reported during the first cycle after a median of
eight days of treatment while in three patients it oc-
curred on day 1 or on day 2 of the second cycle. Treat-
ment had to be interrupted after eight days in two
patients, one of them treated at 40 mg/nr/d and the
other at 50 mg/nr/d, because of grade 2 fever with chills
despite paracetamol premedication. The fever did not
recur after JM216 discontinuation. Overall, drug fever
occurred in four of six patients treated at 50 mg/m2,
with discontinuation of treatment in one of them; in two
of three patients who continued the treatment one did
not present fever, while in two it was possible to either
prevent or control the symptoms by premedication with
paracetamol.
Antitumour response
One patient with hormone-resistent metastatic prostate
cancer, failing anthracyclines, etoposide and 5-FU con-
tinuous infusion, obtained complete relief of tumour
pain due to retroperitoneal nodes with no further need
of analgesics after the first two cycles at 45 mg/nr/d.
CT scan evaluation showed stable disease lasting four
months. One patient with locally advanced malignant
mesothelioma received eight cycles of JM216 at 50 mg/m2
as initial treatment, with stable disease on chest CT but
complete resolution of pericardial effusion and control of
tumour-related pain and fever of nine months'duration.
Pharmacokinetics
The pharmacokinetics of JM216 on days 1 and 14 was
studied in 15 patients treated at doses ranging from 20
mg/m2/d to 50 mg/m2/d.
Figure 2 shows the plasma pharmacokinetic profiles
of Pt and UPt of four patients who received 45 mg/m2.
JM216 was rapidly absorbed, with Pt and UPt detect-
1000,
10-
1
A
a
pt 8 • Pt; o UPt
pt 9 • Pt; D UPt
pt 10 * P t ; OUPt
pt 11 A Pt; A UPt
]\r0 4h 8h 12h 6h 12h 18h 24hJL 16 21 28
DAY1 DAY 7 DAY 14 DAYS
Figure 2. Plasma levels of total platinum (Pt) and plasma ultrafiltrate platinum (UPt) in patients treated with JM216 at 45 mg/m2.
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Table 6. Pharmacokinetic parameters (mean ± SD) of plasma ultrafiltrate platinum (UPt).
Dose (mg/m2)
20
30
35
40
45
50
Cmax (ng/ml)
Day 1
10
16. 14
18
23.25
40 ± 10(4)
23 ± 5 (4)
Day 14
29
34, 19
33
30,38
54 + 20 (4)
22,49
Tmax (h)
Day 1
6
1,4
2
2.2
2 ± 0 (4)
2.5 ±0.6 (4)
Day 14
0.5
1,6
4
4, 1
1.3 ±0.9 (4)
2,3
AUC 24-hour (ng/ml h)
Day 1
_
230
213
180,347
409 ± 106(4)
232 ± 29 (4)
Day 14
528
505,338
657
448,703
883 ± 442 (4)
420,475
T1/2P(h)
Day 1
_
15
14
13, 10
8 + 3 (4)
10 ±5 (4)
Day 14
3
16,29
30
10,45
5 ±4(4)
30, 13
In brackets, number of patients studied.
Table 7. Pharmacokinetic parameters (mean ± SD) of total platinum (Pt).
Dose (mg/m2)
20
30
35
40
45
50
Cmax (ng/ml)
Day 1
90
150,76
86
121 ± 12(3)
145 ± 18(4)
135 ±21 (4)
Day
314
660,
132
502
400
335,
14
194
±211(3)
± 53 (4)
190
Tmax (h)
Day 1
6
3
2
2.3 ±0 6(3)
2.7 + 0.5(4)
2.5 ±0.6 (4)
Day
4
2
4
3± 1
3.5 +
1.3
14
.7
: 1
(3)
.7(4)
AUC 24-hour (ng/ml h)
Day 1
_
2373
1459
1797 ± 168(3)
1887 ±410 (4)
2126 ±288 (4)
Day 14
6385
13220,3753
3418
9794 ±5142 (3)
7071 ±653(4)
6942,3025
T,,2P(h)
Dayl
_
16
14
13 ±6.5 (3)
14 ±3 (4)
39 ± 9 (4)
Day 14
14
45,25
29
52 ±25 (3)
10 ±6 (4)
71,23
In brackets, number of patients studied.
able in plasma as early as 30 min after the administra-
tion. On day 1 Pt and UPt peak levels were achieved in
most cases within 3 hours, with median Tmax values of
2.5 and 2 h, respectively. Elimination was variable and
slow for Pt and UPt; both platinum species were detect-
able at the time of subsequent dosing, with platinum
accumulation in plasma during the cycle.
The main pharmacokinetic parameters are reported
in Tables 6 and 7. At all dose levels, the Cmax and AUC
of Pt on day 14 were two to five times higher than those
of day 1, while a lower increase of 1.5-2 times was
reported for UPt. Cmax and AUC values of UPt and Pt
increased with the dose, with some overlap among differ-
ent dose levels due to the high interpatient variability.
Only the Cmax of Pt and UPt on day 1 showed a
linear relation to the dose (Pt: r - 0.67, P < 0.01; UPt:
r - 0.60, P < 0.05). Ti/2(3 appeared variable among
patients, ranging from eight to 15 hours for UPt and
from 13 to 39 hours for Pt on day 1, from three to 30
hours for UPt and from 10 to 71 hours for Pt on day 14.
Long terminal half-lives were found after the last ad-
ministration on day 14, with Pt and UPt concentrations
of, respectively, 100 ng/ml and 20 ng/ml still detectable
two weeks after the last dosing.
In one patient who had limited pharmacokinetic
evaluations in subsequent courses, plasma values of
12 ng/ml of UPt and 119 ng/ml of Pt three weeks after
the end of the third course and of 15 ng/ml and 140
ng/ml three weeks after the end of the fourth course,
were found, suggesting a very prolonged exposure to
both platinum species.
The mean plasma-free fractions (ratio of ultrafiltrate
and total plasma AUC) were 15.3% (range 9.7%-25.0%)
and 10.5% (3.8%-19.2%) on days 1 and 14, respectively.
The 24-hour urinary excretion of Pt varied from 1.5% to
18% of the dose.
Renal function, as assessed by creatinine clearance
(CrCl) on 24-hour urine collection, was inversely pro-
portional to the sum of UPt AUC on days 1 and 14
(r = 0.71, P < 0.05). No pharmacokinetic information is
available in patients who presented diarrhea or who
were taking loperamide to control this side effect of the
treatment.
In one patient with mesothelioma who underwent
pleural drainage (total volume 2500 ml), a Pt concen-
tration of 63 ng/ml was found in the pleural fluid eight
hours after the last dose of JM216. This concentration
was half of the corresponding plasma Pt concentration
and three times higher than the plasma UPt concentra-
tion, indicating that 0.45% of the daily dose was distrib-
uted in the pleural fluid.
No significant relationships could be established be-
tween Pt AUC or UPt AUC and myelotoxicity or GI
toxicity.
Recommended doses for phase II studies
The doses recommended for phase II studies are 40
mg/m2/d for 14 consecutive days for patients with exten-
sive prior treatment and 45 mg/m~/d for 14 consecutive
days for patients with only limited/no prior treatment,
to be repeated every five weeks with oral 5-HT3 antago-
nists as antiemetic prophylaxis.
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Discussion
The daily administration of JM216 for 14 consecutive
days was investigated in the interest of improving the
tolerability of treatment and developing a regimen suit-
able for combination studies on a chronic basis. While
thrombocytopenia was the main toxicity in the day x 5
regimen [5], neutropenia was dose-limiting in the day x
14 schedule. Myelotoxicity was moderate and delayed,
with an optimal interval before retreatment of five weeks.
The characteristics of prior therapy were risk factors for
myelotoxicity, and MTDS were reached at 45 mg/nr/d
and 50 mg/irr/d in patients with extensive (at least
two prior chemotherapies) or limited/no prior treatment,
respectively. The corresponding doses for phase II studies
were 45 mg/m2/d and 40 mg/nr/d. Neutropenia was
moderate at 50 mg/nr/d; this dose, however, was con-
sidered the MTD and too high for phase II evaluation
because of the occurrence of drug fever during the first
cycle in five of six patients treated.
The occurrence of moderate to severe vomiting in 22%
of cycles at doses equal to or greater than 35 mg/m2/d
suggests that oral antiemetic prophylaxis with 5-HT3
antagonists should be given. With respect to other non-
hematologic toxicities, diarrhea, which occurred in 28%
of cycles irrespective of dose, was also observed by
Me Keage et al., while drug fever, controlled or pre-
vented by paracetamol, was a feature exclusive to the
present study.
Antitumour activity was observed in one patient with
metastatic prostate cancer progressing after anthracy-
clines, and in one patient with malignant mesothelioma
who showed a less than 50% decrease of pleural lesions
on CT scan but a complete disappearance of tumour-
related pain and fever lasting nine months.
The pharmacokinetics of JM216 was investigated in
the two previous phase I studies, one on a single inter-
mittent [5] and the other on a day x 5 schedule [6]. In the
single intermittent regimen pharmacokinetics was non-
linear at doses equal to or greater than 200 mg/m2,
probably due to saturable absorption and a decrease in
the percentage of the dose excreted in urine at increasing
doses. More promising results were achieved with the
day x 5 schedule, for which linear pharmacokinetics
was reported for doses between 30 mg/m2/d and 140
mg/m2/d, although with a significant inter-patient vari-
ability of AUC. Pt and UPt levels accumulated in plas-
ma from day 1 to day 5 and UPt AUC appeared to be
inversely related to the baseline glomerular filtration
rate, suggesting that JM216 elimination depends to a
minor extent on renal function.
An even higher inter-patient variability of the phar-
macokinetics of JM216 was found in the present study
and only the Cmax of both total and ultrafiltrable
platinum on day 1 was linearly related to the dose. In
contrast to the report of Me Keage et al. [6], we found
no linear relationship to the dose and AUC on days 1
and 14 for Pt and UPt; one reason for this discrepancy
could be the smaller range of doses investigated in our
study (from 20 mg/nr/d to 50 mg/nr/d) as compared to
the one of Me Keage (from 30 mg/nr/d to 140 mg/nr/d),
which might have amplified the overlapping of AUCs
among doses. Another reason for the non-linear kinetics
of UPt may have been the use of filters for ultrafiltration
with a different cut-off from those used by Me Keage et
al. (30,000 Dalton instead of 10,000) which could have
overestimated the UPt measurement. This is supported
by the fact that we determined a free fraction of Pt of
11%-16% higher than the 6%-12% of Me Keage et al.
Also in our study total and ultrafiltrable platinum
accumulated significantly in plasma, and Pt and UPt
levels were still detectable two to three weeks after the
last dose. It seems reasonable to ascribe the UPt levels
determined several days after treatment primarily to
platinum, bound to filtrable macromolecules (e.g., small
peptides), whose pharmacological activity is unknown.
Analogous to that found by Me Keage et al. after five
days of treatment, AUCs on day 14 were about 1.5-2 (for
UPt) and two to six (for Pt) times higher than the AUCs
on day 1; these results suggest that a longer duration of
treatment does not result in a significant increase of Pt
and UPt plasma levels.
The largest increase of six times AUC on day 14 was
reported in the patient who had the lowest CrCl and the
lowest urinary excretion of JM216, suggesting that renal
function could at least partly contribute to pharmacoki-
netics variability. This observation is consistent with the
weak but significant relationship we found between
CrCl and AUC of UPt. Again in contrast to McKeage,
however, we could find no correlation between UPt
AUC and thrombocytopenia.
The significant interpatient variability of neutrope-
nia, which is only partly explained by the characteristics
of prior treatment, might be related to a variety of
reasons such as variability in drug absorption, variability
in the accumulation of UPt levels during treatment and
variability in the production of active or inactive metabo-
lites, four of which have been identified [10]. The occur-
rence of drug fever, variable and unpredictable, and, to a
lesser extent, that of diarrhea with no relationship to the
occurrence of myelotoxicity, might be due to the produc-
tion of toxic species in the GI tract.
The recommended doses of 40 mg/m2/d and 45
mg/m2/d for 14 consecutive days correspond to a total
dose higher than that reached with those recommended
for the day x 5 schedule of 100 mg/m2/d and 120
mg/m2/d. This difference, however, is irrelevant because
of the high interpatient variability of pharmacokinetics
and of the long T|/2(3 of JM216; a shorter duration and
therefore better tolerability were the main criteria for
the choice of the day x 5 schedule. A broad phase II
program with single-agent JM216 given for five consec-
utive days in different tumour types is almost completed,
with confirmation of the phase I toxicity data [11], while
combination studies with etoposide have been started in
sensitive tumour types because of the therapeutic syn-
ergy observed in the P38s leukemia model [12].
The administration of JM216 on a day x 14 schedule
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has produced nausea and vomiting comparable to that
observed with the day x 5 regimen but of longer dura-
tion. In addition, the pharmacokinetics and pharmaco-
dynamics of the drug were highly variable, mainly at the
higher doses evaluated of 45 mg/m2/d and 50 mg/m2/d.
One theoretical advantage of the day x 14 regimen could
be the prolonged exposure to still-cytotoxic UPt and Pt
concentrations and the persistence two weeks after dos-
ing of Pt and UPt plasma levels in the range of those
required for radiosensitization. This might be useful if
low dose single agent JM216 is given in combination
with radiation. On the other hand, when JM216 was
administered with UFT/leucovorin for 14 days, nausea
and vomiting were dose limiting at daily doses of 20
mg/m2 of JM216 and 300 mg/m2 of UFT, respectively
[13]. Different schedules of treatment with JM216, which
take into account also its pharmacokinetic profile, should
be therefore evaluated for combination studies with
UFT/leucovorin.
Note
1. Common Toxicity Criteria from Cancer Therapy Evaluation Pro-
gram, Division of Cancer Treatment, National Cancer Institute,
Bethesda, MD.
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